Obstetrics & gynaecology

Survival similar with debulking by laparotomy, laparoscopy

(HealthDay)—For women with epithelial ovarian cancer, three-year survival rates are similar for women undergoing debulking by laparotomy or laparoscopy, according to a study published in the May issue of Obstetrics & Gynecology.

Oncology & Cancer

Researchers use new imaging to show key enzyme in ovarian cancer

A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive. Currently, epithelial ovarian cancer patients ...

Oncology & Cancer

Combination therapy improved chemoresistance in ovarian cancer

Treating ovarian cancer with platinum-based chemotherapy drugs such as cisplatin is initially very effective, with about four out of five patients responding favorably. However, most of these patients quickly become resistant ...

Oncology & Cancer

Recs developed for neoadjuvant chemo in ovarian cancer

(HealthDay)—Guidelines have been developed for neoadjuvant chemotherapy use for newly diagnosed, advanced ovarian cancer. The clinical practice guideline was published online Aug. 8 in the Journal of Clinical Oncology.

Oncology & Cancer

Simplifying access to gene testing for women with ovarian cancer

A new streamlined approach to genetic testing for women with ovarian cancer provides testing rapidly and affordably, allowing many more patients to benefit from personalised cancer management and their relatives to benefit ...

Obstetrics & gynaecology

Hormone Tx no harm after nonserous epithelial ovarian CA

(HealthDay)—For women with nonserous epithelial ovarian cancer, hormone therapy (HT) after treatment does not reduce survival, according to a study published in the May issue of Obstetrics & Gynecology.

page 3 from 6